Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases

被引:36
作者
Zielinska, E
Niewiarowski, W
Bodalski, J
Stanczyk, A
Bolanowski, W
Rebowski, G
机构
[1] Med Univ Lodz, Clin Pediat 2, PL-94274 Lodz, Poland
[2] Polish Acad Sci, Ctr Mol & Macromol Studies, Dept Bioorgan Chem, PL-00901 Warsaw, Poland
[3] Med Univ Lodz, Inst Pediat, Allergol Outpatient Clin, PL-94274 Lodz, Poland
关键词
D O I
10.1016/S0009-9236(97)90083-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The overrepresentation of phenotypically slow acetylators among patients with atopic allergy has been reported in previous studies. The N-acetyltransferase coding gene has not yet been investigated in allergic diseases. This study was designed to determine the differences in the distribution of mutation frequency and genotypes that encode normal and defective activity of N-acetyltransferase in children with atopic allergies compared with healthy children. In 56 children with documented inhalational, food, or mixed allergies and in 100 healthy control children with no clinical or laboratory signs of allergy, the genotype coding for N-acetyltransferase was identified by means of the polymerase chain reaction followed by analysis of restriction fragment length polymorphism. Nucleotide transitions in the following positions were investigated: 481 C-->T, 590 G-->A, 803 A-->G, and 857 G-->A, which enabled the identification of six genotypes, including the wild-type (wt) allele, and 16 genotypes, including mutated alleles (homozygotic and herterozygotic). The statistical analysis showed significant differences in the distribution of the frequency of the occurrence of mutated alleles and genotypes between the two groups of children. In 51 children (91%) with allergy, genotypes that encode acetylation defect were found; genotypes that code for normal N-acetyltransferase were observed in only five allergic children (9%). In the control group the distribution of genotypes coding for normal and defective N-acetyltransferase activity is 38% and 62%, respectively. Thus study enabled the conclusion that the slow acetylation genotype is a genetic marker of predisposition to atopy.
引用
收藏
页码:635 / 642
页数:8
相关论文
共 35 条
  • [1] MOLECULAR ANALYSIS OF THE ARYLAMINE N-ACETYLTRANSFERASE POLYMORPHISM IN A SPANISH POPULATION
    AGUNDEZ, JAG
    MARTINEZ, C
    OLIVERA, M
    LEDESMA, MC
    LADERO, JM
    BENITEZ, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (02) : 202 - 209
  • [2] BIOGENIC-AMINE ACETYLATION - AN ADDITIONAL FUNCTION OF THE N-ACETYLTRANSFERASE FROM FASCIOLA-HEPATICA
    AISIEN, SO
    WALTER, RD
    [J]. BIOCHEMICAL JOURNAL, 1993, 291 : 733 - 737
  • [3] GENOTYPE-PHENOTYPE DISCORDANCE FOR HUMAN ARYLAMINE N-ACETYLTRANSFERASE (NAT2) REVEALS A NEW SLOW-ACETYLATOR ALLELE COMMON IN AFRICAN-AMERICANS
    BELL, DA
    TAYLOR, JA
    BUTLER, MA
    STEPHENS, EA
    WIEST, J
    BRUBAKER, LH
    KADLUBAR, FF
    LUCIER, GW
    [J]. CARCINOGENESIS, 1993, 14 (08) : 1689 - 1692
  • [4] MOLECULAR MECHANISM OF SLOW ACETYLATION OF DRUGS AND CARCINOGENS IN HUMANS
    BLUM, M
    DEMIERRE, A
    GRANT, DM
    HEIM, M
    MEYER, UA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) : 5237 - 5241
  • [5] ACETYLATION PHENOTYPE AND CUTANEOUS HYPERSENSITIVITY TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN HIV-INFECTED PATIENTS
    CARR, A
    GROSS, AS
    HOSKINS, JM
    PENNY, R
    COOPER, DA
    [J]. AIDS, 1994, 8 (03) : 333 - 337
  • [6] CASCORBI I, 1995, AM J HUM GENET, V57, P581
  • [7] GENETICALLY-DETERMINED VARIABILITY IN ACETYLATION AND OXIDATION - THERAPEUTIC IMPLICATIONS
    CLARK, DWJ
    [J]. DRUGS, 1985, 29 (04) : 342 - 375
  • [8] Crimi N, 1996, ALLERGY, V51, P157
  • [9] DEGUCHI T, 1992, J BIOL CHEM, V267, P18140
  • [10] Dyduch A, 1996, Pediatr Pol, V71, P391